Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
CRISPR Market Analysis By Industry Growth, Size, Share, Demand, Trends and Research Report
11:19am, Thursday, 11'th Jun 2020
Jun 11, 2020 (AmericaNewsHour) --
Global CRISPR Market Size Study by Application(Genome Editing, Genetic Engineering, Gene Library, CRISPR Plasmid, Human...
Edited Transcript of NTLA earnings conference call or presentation 7-May-20 12:00pm GMT
03:48am, Thursday, 11'th Jun 2020
Q1 2020 Intellia Therapeutics Inc Earnings Call
Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in
Xconomy: Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More
03:33pm, Friday, 05'th Jun 2020
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
04:37am, Friday, 05'th Jun 2020
Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
12:00am, Friday, 05'th Jun 2020
Stocks Analysis by Zacks Investment Research covering: Agenus Inc, Intellia Therapeutics Inc. Read Zacks Investment Research's latest article on Investing.com
Regeneron has both added to its current growth drivers and developed an impressive pipeline that should fuel performance throughout the decade. Eylea will benef
Edited Transcript of NTLA earnings conference call or presentation 7-May-20 12:00pm GMT
05:55am, Thursday, 04'th Jun 2020
Q1 2020 Intellia Therapeutics Inc Earnings Call
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs June 3)
Arena Pharmaceuticals, Inc. (...
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
01:56pm, Wednesday, 03'rd Jun 2020
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
Better Buy: CRISPR Therapeutics vs. Intellia
11:54am, Wednesday, 03'rd Jun 2020
The gene editing revolution is taking the market by storm, garnering the attention of large pharma companies and investors alike. This technology allows scientists to change an organism's DNA and can
Why Editas Medicine Is Now the CRISPR Stock to Really Watch
11:02am, Wednesday, 03'rd Jun 2020
It's more than 2 1/2 times the size of Editas Medicine (NASDAQ: EDIT) and nearly four times larger than Intellia Therapeutics (NASDAQ: NTLA). While CRISPR Therapeutics and Intellia have captured in
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
02:00am, Wednesday, 03'rd Jun 2020
CAMBRIDGE, Jun 02, 2020 (GLOBE NEWSWIRE via COMTEX) --
CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a...
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
01:00am, Wednesday, 03'rd Jun 2020
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing
